PSMD10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17978557	0.69	1/20
SCHEMBL17978568	0.65	1/20
SCHEMBL5068482	0.65	1/20
SCHEMBL29768658	0.59	1/20
SCHEMBL29768597	0.58	1/20
SCHEMBL19126510	0.55	1/20
SCHEMBL29084498	0.54	1/20
SCHEMBL19553894	0.54	1/20
SCHEMBL16991673	0.53	1/20
SCHEMBL31227601	0.52	1/20
SCHEMBL5870583	0.52	1/20
SCHEMBL13252835	0.52	1/20
SCHEMBL30325035	0.52	1/20
SCHEMBL30325226	0.52	1/20
SCHEMBL29084501	0.52	1/20
SCHEMBL29768576	0.52	1/20
SCHEMBL29828500	0.52	1/20
SCHEMBL16511356	0.51	1/20
SCHEMBL28662792	0.51	1/20
SCHEMBL2881523	0.50	1/20

Clinical trials — most relevant to PSMD10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis	PHASE1/PHASE2	COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Implementation of Molecular Diagnostic Pathways	nan	UNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Effect of Diaphragm Stimulation During Surgery	nan	COMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia	nan	RECRUITING
Study of Constitutional Platelet Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMD10 binder may also engage these)

Protein	Name	Similarity
Q9Z2X3	—	1.000	Q9Z2X3 →
Q9Z2X2	—	0.996	Q9Z2X2 →
Q8BTI7	—	0.987	Q8BTI7 →
Q505D1	—	0.983	Q505D1 →
Q5ZLC8	—	0.983	Q5ZLC8 →
B2RXR6	—	0.983	B2RXR6 →
Q8N8A2	—	0.982	Q8N8A2 →
ANKRD52	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C	0.982	landscape →
O15084	—	0.982	O15084 →
Q53RE8	—	0.981	Q53RE8 →
Q502K3	—	0.981	Q502K3 →
Q0P5B9	—	0.980	Q0P5B9 →
Q5F478	—	0.980	Q5F478 →
Q9D2X0	—	0.975	Q9D2X0 →
Q6RI86	—	0.972	Q6RI86 →
Q9Y575	—	0.972	Q9Y575 →
Q5ZIJ9	—	0.971	Q5ZIJ9 →
Q8BLA8	—	0.971	Q8BLA8 →
Q6GNY1	—	0.968	Q6GNY1 →
A6NHY2	—	0.967	A6NHY2 →
Q9Y574	—	0.967	Q9Y574 →
Q9WV71	—	0.967	Q9WV71 →
Q14DN9	—	0.967	Q14DN9 →
Q9BGT9	—	0.967	Q9BGT9 →
TRPA1	Transient receptor potential cation channel subfamily A member 1	0.966	landscape →
Q804S5	—	0.966	Q804S5 →
Q499M5	—	0.966	Q499M5 →
Q80SY4	—	0.966	Q80SY4 →
Q9P2R3	—	0.966	Q9P2R3 →
Q810B6	—	0.966	Q810B6 →